...
首页> 外文期刊>Journal of neuro-oncology. >Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis
【24h】

Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis

机译:胶质瘤患者患者的分子遗传和临床病理预后因素显示总1p19q损失:染色体19p的增益与组织学级III与患者预后的负相关

获取原文
获取原文并翻译 | 示例

摘要

Although 1p19q codeleted gliomas are the most favorable molecular subgroup of lower-grade gliomas, there are cases with early recurrence or short survival. The objective of this study was to elucidate molecu-lar- genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss. The study included 57 consecutive patients with codeleted gliomas who were operated at Keio University Hospital between 1990 and 2010. These patients were assessed for chromosomal copy number aberrations, promoter methylation status of the O6-methylguanine-DNA methyltransferase gene (MGMT), and demographic and clinicopathological prog-nostic factors in diffuse gliomas. No significant difference was observed in the overall survival (OS) of the patients with respect to age (>= 40 years vs. < 40 years), degree of resection, maximum tumor diameter (>= 5 cm vs. < 5 cm), histological subtype, and MGMT promoter methylation sta-tus. Gain of chromosome 19p and grade III histology were associated with shorter OS (P = 0.019, 0.061, respectively). Gain of 19p and histological grade III might be negative prognostic factors for the patients with gliomas showing total 1p19q loss. Further investigation is warranted to con-firm these notions.
机译:虽然1P19Q Codeleted Gliomas是较低级胶质瘤最有利的分子亚组,但存在早期复发或存活率的病例。本研究的目的是阐明胶质瘤患者的分子遗传和临床病理预后因素,显示出总数1P19Q损失。该研究包括在1990年至2010年间在Keio大学医院运营的57名连续Gliomas患者。这些患者被评估为染色体拷贝数像差,O6-甲基胍甲基-DNA甲基转移酶基因(MGMT)的启动子甲基化状态,以及人口统计弥漫性胶质瘤中的临床病理学术语。在年龄(> = 40岁与<40岁)的患者的整体存活率(OS)中没有观察到显着差异,切除程度,最大肿瘤直径(> = 5cm,<5cm),组织学亚型,和MgMT启动子甲基化STA-TU。染色体19P和III级组织学的增益与较短的OS(P = 0.019,0.061)相关。 19P的增益和组织学等级III可能是胶质瘤患者的负预后因素,显示出总额1P19Q损失。进一步调查是为了确认这些概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号